Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

County Public Schools has joined dozens of other school systems and institutions in suing pharmaceutical and pharmacy companies, alleging that the companies manipulated the prices of insulin and other ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.